Angela Cenci Nilsson
Titel
professor
046-2221431
Angela [dot] Cenci_Nilsson [at] med [dot] lu [dot] se
Publikationer (hämtat ur Lunds universitets publikationsdatabas)
författare
- 2012
- A Model of GDNF Gene Therapy in Mice with 6-Hydroxydopamine Lesions: Time Course of Neurorestorative Effects and ERK1/2 Activation
- Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
- Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
- In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
- Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.
- 2011
- Apoptosis-inducing factor mediates dopaminergic cell death in response to lps-induced inflammatory stimulus Evidence in Parkinson's disease patients.
- Cortical resonance around 80 Hz is linked to dyskinesia after levodopa treatment in a rodent model of Parkinson’s disease
- Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
- Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
- Mechanisms underlying cortical resonance in levodopa-induced dyskinesia
- Parkinson disease: Poor results for retinal cell transplants in Parkinson disease.
- Putaminal Upregulation of FosB/Delta FosB-Like Immunoreactivity in Parkinson's Disease Patients with Dyskinesia
- The locus coeruleus Is Directly Implicated in L-DOPA-Induced Dyskinesia in Parkinsonian Rats: An Electrophysiological and Behavioural Study
- Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
- 2010
- A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
- Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease
- Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
- Immunohistochemical Detection of Fosb/Delta fosb-Like Proteins Maps Areas of Maladaptive Neuroplasticity in the Post-Mortem Parkinsonian Brain
- Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.
- L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
- Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
- Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.
- Post- Versus Pre-Synaptic Plasticity
- Recent Advances In Parkinson'S Disease: Translational And Clinical Research Preface
- 2009
- Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
- Chronic intermittent L-DOPA treatment induces changes in dopamine release
- Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease.
- Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signalling.
- Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
- Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
- 2008
- 2007
- Advances in understanding l-DOPA-induced dyskinesia.
- Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
- Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia.
- Expression pattern of JunD after acute or chronic l-DOPA treatment: Comparison with DeltaFosB.
- High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence
- L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
- Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model.
- Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia.
- Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
- Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors
- The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with l-DOPA: Relation to dose and route of administration.
- 2006
- Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease
- Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
- Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
- On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease.
- Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia
- Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
- Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
- The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
- 2005
- 2004
- A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
- Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism
- Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy)
- Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
- 2003
- Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
- Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
- Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment.
- 2002
- Animal models of neurological deficits: how relevant is the rat?
- L-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function.
- Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
- Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
- 1994
